Trailing-twelve-month (TTM) revenue is $491.95 Million with a year-over-year growth of (12.17%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $113,953,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $166,364,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $105,865,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $105,772,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-19 |
| TTM revenue | $491,954,000 |
Current P/S: $2,054,685,473 market capitalization ÷ $491,954,000 TTM revenue = 4.18x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:00:28.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $105.77M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:01:04.395Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD |
|---|---|
| Humira | $12.2B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Asia | $7M | N/A | N/A | N/A |
| Asia And Other | N/A | $10M | N/A | N/A |
| Europe | $39M | $64M | $158M |
$491.95M
$491.95 Million
(12.17%)
vs. $560.12M a year ago (TTM)
+69.03%
5 Year compound annual growth rate
1 Year
(12.17%)
3 Year
+98.16%
5 Year
+69.03%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $586.32M | +$96.64M | +19.74% |
| 2024 | $489.68M | +$398.25M | +435.56% |
| 2023 | $91.43M | +$8.40M | +10.12% |
| 2022 | $83.03M | +$46.26M | +125.79% |
| 2021 | $36.77M | ($29.84M) | (44.80%) |
| 2020 |
TTM Growth
(12.17%)
3-Year CAGR
+98.16%
5-Year CAGR
+69.03%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:01:04.395Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $307M |
| North America | $31M | $18M | N/A | N/A |
|---|
| Other Geographical Area | $6M | N/A | N/A | N/A |
|---|
| Rest Of The World | N/A | N/A | $59M | $38M |
|---|
| UNITED STATES | N/A | N/A | $273M | $241M |
|---|
| $66.62M |
| +$34.70M |
| +108.71% |
